DEMO

Log In | Sign Up



Charles River Laboratories

Selected Articles

2025-08-13
Plos.org
Anti-obesity compounds, Semaglutide and LiPR, and PrRP do not change the proportion of human and mouse POMC+ neurons
2025-08-13
ETF Daily News
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Charles Schwab Investment Management Inc.
2025-08-12
ETF Daily News
Federated Hermes Inc. Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)
2025-08-12
GlobeNewswire
Virology and Bacteriology Business Analysis Report 2025 | Market to Reach $2.7 Billion by 2030 - Biopharmaceutical Pipeline Diversification Spurs Demand for Dual-Discipline Expertise and Platforms
2025-08-11
ETF Daily News
William Blair Has Optimistic Outlook of CRL FY2025 Earnings
2025-08-10
ETF Daily News
Barclays Increases Charles River Laboratories International (NYSE:CRL) Price Target to $165.00
2025-08-09
ETF Daily News
Wall Street Zen Upgrades Charles River Laboratories International (NYSE:CRL) to Strong-Buy
2025-08-08
ETF Daily News
Avantax Advisory Services Inc. Grows Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
2025-08-06
Biztoc.com
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing
2025-08-06
Barchart.com
Stocks Trade Higher on Solid Earnings and Fed Rate Cut Speculation

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. US1598641074 www.criver.com